Brian Pepin is the CEO and founder of Rune Labs. Brian holds an MSEE in electrical engineering from UC Berkeley and a BSEE from the University of Washington. Prior to starting Rune, Brian spent nearly five years at Verily Life Sciences.
Top 3 Takeaways

* It makes sense to use neuromodulation therapies for neurological and psychiatric disorders that inherently fluctuate over time.
* Neuromodulation data is siloed and that slows down research and translation.
* Closed-loop DBS can enable novel, more efficacious therapies.

Show Notes

* [0:47] Brian’s background.
* [1:50] The Google phase.
* [3:10] Brian’s transition into Rune Labs.
* [3:30] Rune in a nutshell.
* [4:32] Unmet needs for brain diseases.
* [5:58] Why neuromodulation instead of drugs.
* [7:30] Need for adaptive therapies.
* [8:53] Impact of neuromodulation in Parkinson’s Disorder.
* [10:54] Who fits the bill for DBS.
* [13:30] Siloed data in neuromodulation.
* [15:15] Competition in DBS.
* [16:45] Initial application of closed-loop DBS is auto-tune.
* [17:30] Closed-loop can enable therapies.
* [19:03] Software development in DBS devices.
* [20:10] Partnerships between medical device companies and AI companies.
* [21:27] Long-term vision for Rune.

Selected Links

* Strive PD patient-facing application

Related Podcasts

* 021 – Cory Inman
* 020 – Mary Beth Henderson
* 016 – Jim Cavuoto

Disclaimer